Tokyo, Oct 30, 2009 - (JCN Newswire) - Eisai Co., Ltd. today announced preliminary results from a recently completed Phase III study with E7389 (generic name: eribulin mesylate, "eribulin"), discovered and developed by the Company, in patients with locally advanced
» Full text »
